On Jun 30, 2021 Spero Therapeutics (Nasdaq: SPRO) announced $40 Million Equity Investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.

About the company: Spero Therapeutics is located at United States, North America. The company is a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases.

On Jun 30, Spero Therapeutics and Pfizer also also entered into a licensing agreement for SPR206, Spero’s intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting.  

Company website: sperotherapeutics.com/